TCL Archive NCAB Okays Effort To Relax $5 Million Limit On Center Core Grants In Cancer Act Renewal November 19, 1976
TCL Archive FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says. January 14, 2005
TCL Archive NCAB, DRCCA Board Asked To Consider Dripping All Staff Investigator Salary Support From Core October 17, 1980
TCL Archive Growth Of The Cost of Drugs Slows to 5.4 Percent per Year; 21 Therapies Launched in 2 Years May 9, 2014
